Human Granulocyte ColonyStimulating Factor Injection (rhG-CSF)
Market
Recombinant Human Granulocyte ColonyStimulating Factor Injection (rhG-CSF) Market
Scope: Industry Analysis, Market Size, Growth, Trends Till 2031
Request Sample Report
Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Market Size and Growth
The Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhGCSF) market is experiencing significant growth, driven by its increasing use in chemotherapy-induced neutropenia and related conditions. Current market size is estimated at approximately $XX billion, with projected expansion due to rising healthcare demands and advancements in biotechnology innovations, enhancing treatment protocols globally.
Companies Covered
(Covid 19 Impact Covered)
◍ Abbott
◍ Amgen
◍ Arven Pharmaceuticals
◍ Biocon
◍ Cadila Pharmaceuticals
◍ Dr.Reddy's Laboratories
◍ Emcure Pharmaceuticals
◍ Intas Pharmaceuticals
◍ Kyowa Kirin
◍ Novartis
◍ Pfizer
◍ Reliance Life Sciences
◍ Harbin Pharmaceutical
◍ North China Pharmaceutical
◍ Jiuyuan Gene
◍ Kexing Biopharm
◍ Qilu Pharmaceutical
The Recombinant Human Granulocyte ColonyStimulating Factor (rhG-CSF) market features companies like Amgen and Novartis leading with innovative therapies. These firms enhance market growth through partnerships, expanding indications, and optimizing production. Notable sales include Amgen's $1 billion in 2022 and Novartis's substantial market share, driving overall industry expansion.
◍ Quangang Pharmaceutical
Request Sample Report
Market Segmentation
By Application
Myelosuppressive Chemotherapy
Leukemia Chemotherapy
Others
Request Sample Report
By Product
Vials
Prefilled
Market Growth
Request Sample Report
$ X Billion USD
